日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Pre-clinical safety and efficacy of human induced pluripotent stem cell-derived products for autologous cell therapy in Parkinson's disease.

人类诱导多能干细胞衍生产品用于帕金森病自体细胞治疗的临床前安全性和有效性

Jeon Jeha, Cha Young, Hong Yean Ju, Lee In-Hee, Jang Heejin, Ko Sanghyeok, Naumenko Serhiy, Kim Minseon, Ryu Hannah L, Shrestha Zenith, Lee Nayeon, Park Tae-Yoon, Park HoeWon, Kim Seo-Hyun, Yoon Ki-Jun, Song Bin, Schweitzer Jeffrey, Herrington Todd M, Kong Sek Won, Carter Bob, Leblanc Pierre, Kim Kwang-Soo

Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease

用于治疗帕金森病的个性化iPSC衍生多巴胺祖细胞

Schweitzer, Jeffrey S; Song, Bin; Herrington, Todd M; Park, Tae-Yoon; Lee, Nayeon; Ko, Sanghyeok; Jeon, Jeha; Cha, Young; Kim, Kyungsang; Li, Quanzheng; Henchcliffe, Claire; Kaplitt, Michael; Neff, Carolyn; Rapalino, Otto; Seo, Hyemyung; Lee, In-Hee; Kim, Jisun; Kim, Taewoo; Petsko, Gregory A; Ritz, Jerome; Cohen, Bruce M; Kong, Sek-Won; Leblanc, Pierre; Carter, Bob S; Kim, Kwang-Soo

Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins

通过直接递送重编程蛋白生成人诱导多能干细胞

Kim, Dohoon; Kim, Chun-Hyung; Moon, Jung-Il; Chung, Young-Gie; Chang, Mi-Yoon; Han, Baek-Soo; Ko, Sanghyeok; Yang, Eungi; Cha, Kwang Yul; Lanza, Robert; Kim, Kwang-Soo